Exor (ENXTAM:EXO) has quietly slipped over the past year, with shares down around 23% even as its underlying holdings like Ferrari and Stellantis keep executing. That gap is exactly what value focused ...
Philips resolved the Respironics litigation, settling for $1.1 billion. And Exor decided to boost its stake in the company. Supportive shareholders' remuneration is linked to Exor's portfolio results, ...
Exor’s FY24 performance was uninspiring, with Stellantis dragging down the very strong contribution from Ferrari. Recent actions—reducing Ferrari concentration, executing a large buyback, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback